Surrey Heartlands

Joint Formulary & PAD

Sodium zirconium cyclosilicate - Hyperkalaemia

You are here : Home > Formulary Search > Sodium zirconium cyclosilicate - Hyperkalaemia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NICE
Restrictions / Comments :

Documentation

Evidence Review
Sodium Zirconium Cyclosilicate NICE TA599 - Briefing paper Dec19.pdf
Evidence Review
NICE Briefing paper TA599 update Apr22.pdf
Webpage
NICE TA599 Sodium zirconium cyclosilicate for treating hyperkalaemia

PAD Profile

ChemicalSubstance :
Sodium zirconium cyclosilicate
Indication :
Hyperkalaemia
Group Name :
Keywords :
potassium
Brand Names Include :
Lokelma
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Sodium zirconium cyclosilicate is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Hyperkalaemia.

Committee Recommendations (1)

04 Dec 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Area Prescribing Committee recommends sodium zirconium cyclosilicate as a treatment option for the treatment of hyperkalaemia in line with NICE TA599

Sodium zirconium cyclosilicate will be considered RED on the traffic light system

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.